Kasa İnvaziv Mesane Kanserinde Neoadjuvan ve Perioperatif Tedavi Stratejileri: Güncel Yaklaşımlar

Authors

Ozan Deniz Güven
https://orcid.org/0000-0001-9556-835X

Synopsis

Cisplatin-based neoadjuvant chemotherapy before radical cystectomy has been the standard of care for muscle-invasive bladder cancer (MIBC) for nearly two decades; however, it provides a modest survival benefit and is not applicable to cisplatin-ineligible patients. Recent phase III trials have fundamentally changed this approach. In the NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant gemcitabine-cisplatin improved event-free and overall survival. The combination of enfortumab vedotin and pembrolizumab demonstrated an overall survival benefit in both cisplatin-ineligible (KEYNOTE-905/EV-303) and cisplatin-eligible (KEYNOTE-B15/EV-304) patients. This chapter critically reviews the evidence from the cisplatin era, current perioperative strategies, adjuvant immunotherapy and the role of circulating tumor DNA, bladder-sparing approaches, and current guideline recommendations. Limitations such as control arms lagging behind contemporary standards, the lack of head-to-head comparisons, toxicity, and treatment adherence are discussed, and open questions regarding treatment individualization are summarized.

References

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3): 229–263. doi:10.3322/caac.21834

Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. Journal of Clinical Oncology. 2001;19(3): 666–675. doi:10.1200/JCO.2001.19.3.666

Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New England Journal of Medicine. 2003;349(9): 859–866. doi:10.1056/NEJMoa022148

International Collaboration of Trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. Journal of Clinical Oncology. 2011;29(16): 2171–2177. doi:10.1200/JCO.2010.32.3139

Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. European Urology. 2005;48(2): 202–205. doi:10.1016/j.eururo.2005.04.006

Pfister C, Gravis G, Fléchon A, et al. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. The Lancet Oncology. 2024;25(2): 255–264. doi:10.1016/S1470-2045(23)00587-9

Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. The Lancet Oncology. 2011;12(3): 211–214. doi:10.1016/S1470-2045(10)70275-8

Akpınar Ç, Aydoğ E, Şahin B, et al. Contemporary trends in the surgical and systemic management of muscle-invasive bladder cancer: insights from a nationwide multicenter cohort in Turkey over 2 decades. Clinical Genitourinary Cancer. 2026;24(6): 102612. doi:10.1016/j.clgc.2026.102612

Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. Journal of Clinical Oncology. 2018;36(34): 3353–3360. doi:10.1200/JCO.18.01148

Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature Medicine. 2019;25(11): 1706–1714. doi:10.1038/s41591-019-0628-7

Powles T, Catto JWF, Galsky MD, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. New England Journal of Medicine. 2024;391(19): 1773–1786. doi:10.1056/NEJMoa2408154

Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. New England Journal of Medicine. 2021;384(22): 2102–2114. doi:10.1056/NEJMoa2034442

Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. New England Journal of Medicine. 2024;390(10): 875–888. doi:10.1056/NEJMoa2312117

Vulsteke C, Adra N, Danchaivijitr P, et al. Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. New England Journal of Medicine. 2026;394(13): 1257–1269. doi:10.1056/NEJMoa2511674

Galsky MD, Valderrama BP, Maruzzo M, et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. New England Journal of Medicine. 2026;395(4): 338–348. doi:10.1056/NEJMoa2601486

Apolo AB, Ballman KV, Sonpavde G, et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. New England Journal of Medicine. 2025;392(1): 45–55. doi:10.1056/NEJMoa2401726

Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 2021;22(4): 525–537. doi:10.1016/S1470-2045(21)00004-8

Powles T, Kann AG, Castellano D, et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. New England Journal of Medicine. 2025;393(24): 2395–2408. doi:10.1056/NEJMoa2511885

Zlotta AR, Ballas LK, Niemierko A, et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. The Lancet Oncology. 2023;24(6): 669–681. doi:10.1016/S1470-2045(23)00170-5

Galsky MD, Daneshmand S, Izadmehr S, et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nature Medicine. 2023;29(11): 2825–2834. doi:10.1038/s41591-023-02568-1

Geynisman DM, Abbosh PH, Ross E, et al. Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1). Journal of Clinical Oncology. 2025;43(9): 1113–1122. doi:10.1200/JCO-24-01214

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 3.2026, August 6, 2026. (28/09/2026 tarihinde https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417 adresinden ulaşılmıştır).

van der Heijden AG, Bruins HM, Carrion A, et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer (limited text update March 2026). European Association of Urology. (28/09/2026 tarihinde https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer adresinden ulaşılmıştır).

Powles T, Bellmunt J, Compérat E, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2022;33(3): 244–258. doi:10.1016/j.annonc.2021.11.012

AstraZeneca. Treatment combination of durvalumab, tremelimumab and enfortumab vedotin or durvalumab and enfortumab vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or who refuse cisplatin (VOLGA). ClinicalTrials.gov kayıt numarası: NCT04960709. (11/10/2026 tarihinde https://clinicaltrials.gov/study/NCT04960709 adresinden ulaşılmıştır).

AstraZeneca. Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial [Basın bülteni; hakemli bilimsel yayın değildir]. (02/10/2026 tarihinde https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-ev-improves-efs-os-in-bladder-cancer.html adresinden ulaşılmıştır).

Galsky MD. Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder (HCRN GU22-598). ClinicalTrials.gov kayıt numarası: NCT06809140. (11/10/2026 tarihinde https://clinicaltrials.gov/study/NCT06809140 adresinden ulaşılmıştır).

Astellas Pharma Global Development, Inc. An open-label, single-arm, phase 2 study to evaluate enfortumab vedotin plus pembrolizumab for bladder preservation in participants with muscle-invasive bladder cancer (EV-209). ClinicalTrials.gov kayıt numarası: NCT07475806. (11/10/2026 tarihinde https://clinicaltrials.gov/study/NCT07475806 adresinden ulaşılmıştır).

Published

November 16, 2026

License

License